Analysts Are Optimistic We'll See A Profit From Theranexus Société Anonyme (EPA:ALTHX)

By
Simply Wall St
Published
August 29, 2021
ENXTPA:ALTHX
Source: Shutterstock

Theranexus Société Anonyme (EPA:ALTHX) is possibly approaching a major achievement in its business, so we would like to shine some light on the company. Theranexus société anonyme, a biopharmaceutical company, develops drug candidates for the treatment of central nervous system disorders. On 31 December 2020, the €36m market-cap company posted a loss of €4.8m for its most recent financial year. Many investors are wondering about the rate at which Theranexus Société Anonyme will turn a profit, with the big question being “when will the company breakeven?” In this article, we will touch on the expectations for the company's growth and when analysts expect it to become profitable.

See our latest analysis for Theranexus Société Anonyme

According to the 2 industry analysts covering Theranexus Société Anonyme, the consensus is that breakeven is near. They expect the company to post a final loss in 2020, before turning a profit of €8.4m in 2021. Therefore, the company is expected to breakeven roughly 12 months from now or less. How fast will the company have to grow to reach the consensus forecasts that anticipate breakeven by 2021? Working backwards from analyst estimates, it turns out that they expect the company to grow 19% year-on-year, on average, which is relatively reasonable. Should the business grow at a slower rate, it will become profitable at a later date than expected.

earnings-per-share-growth
ENXTPA:ALTHX Earnings Per Share Growth August 30th 2021

We're not going to go through company-specific developments for Theranexus Société Anonyme given that this is a high-level summary, however, keep in mind that typically a pharma company has lumpy cash flows which are contingent on the drug and stage of product development the business is in. So, a double-digit growth rate is not out of the ordinary, particularly when a company is in a period of investment.

Before we wrap up, there’s one issue worth mentioning. Theranexus Société Anonyme currently has a relatively high level of debt. Typically, debt shouldn’t exceed 40% of your equity, which in Theranexus Société Anonyme's case is 55%. A higher level of debt requires more stringent capital management which increases the risk in investing in the loss-making company.

Next Steps:

This article is not intended to be a comprehensive analysis on Theranexus Société Anonyme, so if you are interested in understanding the company at a deeper level, take a look at Theranexus Société Anonyme's company page on Simply Wall St. We've also compiled a list of pertinent factors you should further research:

  1. Historical Track Record: What has Theranexus Société Anonyme's performance been like over the past? Go into more detail in the past track record analysis and take a look at the free visual representations of our analysis for more clarity.
  2. Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on Theranexus Société Anonyme's board and the CEO’s background.
  3. Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.

If you’re looking to trade Theranexus Société Anonyme, open an account with the lowest-cost* platform trusted by professionals, Interactive Brokers. Their clients from over 200 countries and territories trade stocks, options, futures, forex, bonds and funds worldwide from a single integrated account. Promoted


Discounted cash flow calculation for every stock

Simply Wall St does a detailed discounted cash flow calculation every 6 hours for every stock on the market, so if you want to find the intrinsic value of any company just search here. It’s FREE.

Make Confident Investment Decisions

Simply Wall St's Editorial Team provides unbiased, factual reporting on global stocks using in-depth fundamental analysis.
Find out more about our editorial guidelines and team.